Newron Pharmaceuticals, based in Milan, Italy and Morristown, New Jersey, announced topline results from the company’s STARS clinical trial of sarizotan in Rett syndrome. The drug failed to hit the primary or secondary efficacy endpoints.

Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.